Severe Hyperhomocysteinemia in a Patient with Parkinson Disease

Anne-Lise Bjørke-Monsen^{1

2}, Marte-Helene Bjørk^{1

3}, Anette Storstein³, Per Magne Ueland², Ole-Bjørn Tysnes^{1

3}

Affiliations

¹ Department of Clinical Science, University of Bergen, Bergen, Norway.
² Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
³ Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Anne-Lise Bjørke-Monsen et al. Clin Chem. 2022.

. 2022 Mar 4;68(3):396-401.

doi: 10.1093/clinchem/hvab262.

Anne-Lise Bjørke-Monsen^{1

2}, Marte-Helene Bjørk^{1

3}, Anette Storstein³, Per Magne Ueland², Ole-Bjørn Tysnes^{1

3}

¹ Department of Clinical Science, University of Bergen, Bergen, Norway.
² Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
³ Department of Neurology, Haukeland University Hospital, Bergen, Norway.

No abstract available

Keywords: Parkinson disease; benserazide; carbidopa; homocysteine; levodopa; vitamin B6 deficiency.

Comment in

Commentary on Severe Hyperhomocysteinemia in a Patient with Parkinson Disease.
Ho B. Ho B. Clin Chem. 2022 Mar 4;68(3):400-401. doi: 10.1093/clinchem/hvab263. Clin Chem. 2022. PMID: 35243497 No abstract available.
Commentary on Severe Hyperhomocysteinemia in a Patient with Parkinson Disease.
Peake RWA. Peake RWA. Clin Chem. 2022 Mar 4;68(3):401. doi: 10.1093/clinchem/hvab264. Clin Chem. 2022. PMID: 35243498 No abstract available.